GLPG vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GLPG presents a classic 'value trap' profile: while the Graham Number ($84.09) and Intrinsic Value ($163.14) suggest massive undervaluation, the Piotroski F-Score of 2/9 indicates severely weak fundamental health. The company boasts a pristine balance sheet with zero debt and an extraordinary current ratio of 20.14, yet the market is pricing it at a 66% discount to its defensive fair value. This discrepancy, combined with a negative forward P/E and a 0/100 technical trend, suggests the market anticipates a significant reversal of recent growth spikes.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GLPG vs MRK: Head-to-Head Comparison
This page compares Galapagos NV (GLPG) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.